Erbitux adds 5 weeks to lung cancer survival
Lung cancer patients treated in a large clinical trial with ImClone Systems Inc’s Erbitux and chemotherapy lived about five weeks longer than patients treated with chemotherapy alone, according to study results released on Saturday.
This entry was posted on Saturday, May 31st, 2008 at 8:54 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.